The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer

Current Genomics

Volumn 9, Issue 4, 2008, Pages 252-262

  Schettino, Clorinda ^a,b   Bareschino, Maria A ^a,b   Maione, Paolo ^b   Rossi, Antonio ^b   Ciardiello, Fortunato ^a   Gridelli, Cesare ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

Author keywords

tubulin; Adjuvant treatment; EGFR; ERCCI; Molecular markers; NSCLC; RRMI

Indexed keywords

BETA TUBULIN; BETA TUBULIN CLASS 3; BLEOMYCIN; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOTOXIC AGENT; DEATH RECEPTOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FAS LIGAND; GEFITINIB; GEMCITABINE; K RAS PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATINUM DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; RIBONUCLEOTIDE REDUCTASE M2; SURVIVIN; UNINDEXED DRUG;

ADJUVANT THERAPY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA REPAIR; DNA SYNTHESIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENOMICS; HIGH RISK PATIENT; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; PHARMACOGENOMICS; PROBABILITY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 45749108232     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920208784533665     Document Type: Review

References (111)

1. Parkin, D.M., Bray, F., Ferlay, J., Pisavi, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2000, 94: 153-156.
2. Ponn, R.B., Lo Cicero J, III, Daly, B.D.T. Surgical treatment of non small cell lung cancer. In: Shields TW, Lo Cicero JIII, Ponn R, Rusch VW, eds. General thoracic surgery 6th ed. Philadelphia: Lippincot Williams and Wilkins, 2005, 1548-1587.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311: 899-909.
4. Keller, S.M., Adak, S., Wagner, H., Herskovic, A., Komaki, R., Brooks, B.I., Perry, M.C., Livingston, R.B., Johnson, D.H. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N. Engl. J. Med. 2000, 343: 1217-1222.
5. Waller, D., Peake, M.D., Stephens, R.J., Gower, N.H., Milroy, R., Parmar, M.K., Rudd, R.M., Spiro, S.G. Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur. J. Cardiothorac. Surg. 2004, 26: 173-182.
6. Scagliotti, G.V., Fossati, R., Torri, V., Crinò, L., Giaccone, G., Silvano, G., Martelli, M., Clerici, M., Cognetti, F., Tonato, M. Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 2003, 95: 1453-1461.
7. The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 2004, 350: 351-360.
8. Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., Watanabe, Y., Wada, H., Tsuboi, M., Hamajima, N., Ohta, M. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 2004, 350: 1713-1721.
9. Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., Fry, W., Bethune, D., Ayoub, J., Ding, K., Seymour, L., Graham, B., Tsao, M.S., Gandara, D., Kesler, K., Demmy, T., Shepherd, F. National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 2005, 352: 2589-2597.
10. Strauss, G.M., Herndon, J., Maddaus, M.A., Johnstone, D.W., Johnson, E.A., Watson, D.M., Sugarbaker, D.J., Schilsky, R.L., Green, M.R. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B.(CALGB) protocol 9633. J. Clin. Oncol. 2004, 22: abstr 7019.
11. Strauss, G.M., Herndon, J.E., Maddaus, M.A., Johnstone, D.W., Johnson, E.A., Watson, D.M., Sugarbaker, D.J., Schilsky, R.A., Vokes, E.E., Green, M.R. Adjuvant chemotherapy in stage IB non-small-cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. J. Clin. Oncol. 2006, 24: abstr 7007.
12. Douillard, J.Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J.L., Grodzki, T., Pereira, J.R., Le Groumellec, A., Lorusso, V., Clary, C., Torres, A.J., Dahabreh, J., Souquet, P.J., Astudillo, J., Fournel, P., Artal-Cortes, A., Jassem, J., Koubkova, L., His, P., Riggi, M., Hurtcloup, P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]). A randomised controlled trial. Lancet Oncol. 2006, 7: 719-727.
13. Pignon, J.P., Tribodet, H., Scagliotti, G.V., Douillard, J.Y., Shepherd, F.A., Stephens, R.J., Le Chevalier, T. Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. J. Clin. Oncol. 2006, 24: abstr 7008.
14. Pisters, K.M., Evans, W.K., Azzoli, C.G., Kris, M.G., Smith, C.A., Desch, C.E., Somerfield, M.R., Brouwers, M.C., Darling, G., Ellis, P.M., Gaspar, L.E., Pass, H.I., Spigel, D.R., Strawn, J.R., Ung, Y.C., Shepherd, F.A. Cancer Care Ontario; American Society of Clinical Oncology. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J. Clin. Oncol. 2007, 25: 5506-5518.
15. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350: 2129-2139.
16. Paez, J.G., Jänne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304: 1497-1500.
17. Tsao, M.S., Sakurada, A., Cutz, J.C., Zhu, C.Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., Marrano, P., da Cunha Santos, G., Lagarde, A., Richardson, F., Seymour, L., Whitehead, M., Ding, K., Pater, J., Shepherd, F.A. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353: 133-144.
18. Hoeijmakrs, J.H. Nucleotide excision repair: II. From yeast to mammals. Trends Genet. 1993, 9: 211-217.
19. Altaha, R., Liang, X., Yu, J.J. Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int. J. Mol. Med. 2004, 14: 959-970.
20. Rosell, R., Lord, R.V., Taron, M., Reguart, N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002, 38: 217-227.
21. Reed, E., Dabholkar, M., Thornton, K., Thompson, C., Yu, J.J., Bostick-Bruton, F. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol. Rep. 2000, 7: 1123-1128.
22. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J.J., Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 1994, 94: 703-708.
23. Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V.A., Egwuagu, C. Reed, E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst. 1992, 84: 1512-1517.
24. Chen, P., Wiencke, J., Aldape, K., Kesler-Diaz, A., Miike, R., Kelsey, K., Lee, M., Liu, J., Wrensch, M. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers Prev. 2000, 9: 843-847.
25. Park, D.J., Zhang, W., Stoehlmacher, J., Tsao-Wei, D., Groshen, S., Gil, J., Yun, J., Sones, E., Mallik, N., Lenz, H.J. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin. Adv. Hematol. Oncol. 2003, 1: 162-166.
26. Sturgis, E.M., Dahlstrom, K.R., Spitz, M.R., Wei, Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2002, 128: 1084-1088.
27. Yu, J.J., Mu, C., Lee, K.B., Okamoto, A., Reed, E.L., Bostick-Bruton, F., Mitchell, K.C., Reed, E. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat. Res. 1997, 382: 13-20.
28. Viguier, J., Boigo, V., Miquel, C., Pocard, M., Giraudeau, B., Sabourin, J.C., Duereux, M., Sarasin, A., Praz, F. ERCC1 eodon 118 polymorphism is a predictive factor-for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 2005, 11: 6212-6217.
29. Zhou, W., Gurubhagavarula, S., Liu, G., Park, S., Neuberg, D.S., Wain, J.C., Lynch, T.J., Su, L., Christiani, D.C. Excision-repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 2004, 10: 4939-4943.
30. Olaussen, K.A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, Pirker, R., Popper, H.H., Stahel, R., Sabatier, L., Pignon, J.P., Tursz, T., Le Chevalier, T., Soria, J.C. for the IALT Bio Investigators DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355: 983-991.
31. Lord, R.V., Brabender, J., Gandara, D., Alberola, V., Camps, C., Domine, M., Cardenal, F., Sánchez, J.M., Gumerlock, P.H., Tarón, M., Sánchez, J.J., Danenberg, K.D., Danenberg, P.V., Rosell, R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8: 2286-2291.
32. Ceppi, P., Volante, M., Novello, S., Raps, I., Danenberg, K.D., Danenberg, P.V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., Papotti, M;, Scagliotti, G.V. ERCC1 and RRM1 gene expression but not EGFR are predictive of shorter survival in advanced non small cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 2006, 17: 1818-1825. 33
33. Cobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J.M., Provencio, M., Viñolas, N., Paz-Ares, L., Lopez-Vivanco, G., Muñoz, M.A., Felip, E., Alberola, V., Camps, C., Domine, M., Sanchez, J.J., Sanchez-Ronco, M., Danenberg, K., Taron, M., Gandara, D., Rosell, R. Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cane. J. Clin. Oncol. 2007, 25: 2747-2754.
34. Pitterle, D.M., Kim, J.C., Jolicoeur, E.M.C., Cao, Y., O'Briant, K.C., Bepler, G. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm. Genome 1999, 10: 916-922.
35. Davidson, J.D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L.M., Slapak, C.A. An increase in the expression of ribonucleotide reductase subunit 1 large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004, 64: 3761-3766.
36. Bepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., Simon, G. RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J. Clin. Oncol. 2006, 24: 4731-4737.
37. Bepler, G., Sharma, S., Cantor, A., Gautam, A., Haura, E., Simon, G., Sharma, A., Sommers, E., Robinson, L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 2004, 22: 1878-1895.
38. Bepler, G., Zheng, Z., Gautam, A., Sharma, S., Cantor, A., Sharma, A., Cress, W.D., Kim, Y.C., Rosell, R., McBride, C., Robinson, L., Sommers, E., Haura, E. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005, 47: 183-192.
39. Rosell, R., Scagliotti, G., Danenberg, K.D., Lord, R.V., Bepler, G., Novello, S., Cooc, J., Crinò, L., Sánchez, J.J., Taron, M., Boni, C., De Marinis, F., Tonato, M., Marangolo, M., Gozzelino, F., Di Costanzo, F., Rinaldi, M., Salonga, D., Stephens, C. Transcripts in pretreatment biopsies from a three-arm-randomized trial metastatic non-small-cell lung cancer. Oncogene 2003, 22: 3548-3553.
40. Rosell, R., Danenberg, K.D., Alberola, V., Bepler, G., Sanchez, J.J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., Artal, A. Spanish Lung Cancer Group. Ribonucleotide reductase subunit 1 mRNA expression and survival in gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin. Cancer Res. 2004, 10: 1318-1325.
41. Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A., Bepler, G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 2007, 356: 800-808.
42. Simon, G., Sharma, A., Li, X., Hazelton, T., Walsh, F., Williams, C., Chiappori, A., Haura, E., Tanvetyanon, T., Antonia, S., Cantor, A., Bepler, G. Feasibility and Efficacy of Molecular Analysis- Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2007, 19: 2741-2746.
43. Sherr, C.J. Cancer cell cycles. Science 1996, 274: 1672-1677.
44. St Croix, B., Florenes, V.A., Rak, J.W., Flanagan, M., Bhattacharya, N., Slingerland, J.M., Kerbel, R.S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 1996, 2: 1204-1210.
45. Dimanche-Boitrel, M.T., Micheau, O., Hammann, A., Haugg, M., Eymin, B., Chauffert, B., Solary, E. Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int. J. Cancer 1998, 77: 796-802.
46. Eymin, B., Haugg, M., Droin, N., Sordet, O., Dimanche-Boitrel, M.T., Solary, E. P27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 1999, 18: 1411-1418.
47. Masuda, A., Osada, H., Yatabe, Y., Kozaki, K., Tatematsu, Y., Takahashi, T., Hida, T., Takahashi, T., Takahashi, T. Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments. Am. J. Pathol. 2001, 158: 87-96.
48. Filipits, M., Pirker, R., Dunant, A., Lantuejoul, S., Schmid, K., Huynh, A., Haddad, V., André, F., Stahel, R., Pignon, J.P., Soria, J.C., Popper, H.H., Le Chevalier, T., Brambilla, E. Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program. J. Clin. Oncol. 2007, 25: 2735-2740.
49. Pirker, R., Filipits, M., Duriant, A., Pignon, J.P., Soria, J.C., Brambilla, E., Popper, H., André, F., Stahel, R., Le Chevalier, T. IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC: D3-03. J. Thorac. Oncol. 2007, 2: 397-398.
50. Dumontet, C., Sikic, B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 1999; 17: 1061-1070.
51. Jordan, M.A., Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4: 253-265.
52. Katsetos, C.D., Legido, A., Perentes, E., Mork, S.J. Class III β-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J. Child Neurol. 2003, 18: 851-867.
53. Kavallaris, M., Burkhart, C.A., Horwitz, S.B. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br. J. Cancer 1999, 80: 1020-1025.
54. Hari, M., Yang, H., Zeng, C., Canizales, M., Cabral, F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil. Cytoskeleton 2003, 56: 45-56.
55. Kamath, K., Wilson, L., Cabral, F., Jordan, M.A. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 2005, 280: 12902-12907.
56. Mozzetti, S., Ferlini, C., Concolino, P., Filippetti, F., Raspaglio, G., Prislei, S., Gallo, D., Martinelli, E., Ranelletti, F.O., Ferrandina, G., Scambia, G. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 2005, 11: 298-305.
57. Paradiso, A., Mangia, A., Chiriatti, A., Tommasi, S., Zito, A., Latorre, A., Schittulli, F., Lorusso, V. Biomarkers predictive for clinical efficacy of Taxol-based chemotherapy in advanced breast cancer. Ann. Oncol. 2005, 16: 14-19.
58. Urano, N., Fujiwara Y., Doki, Y., Kim, S.J., Noguchi, S., Miyata, H., Takiguchi, S., Yasuda, T., Yan., M., Monden, M. Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int. J. Oncol. 2006, 28: 375-378.
59. Sève, P., Isaac, S., Trédan, O., Souquet, P.J, Pachéco, Y., Pérol, M., Lafanéchère, L., Penet, A., Peiller, E.L., Dumontet, C. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin. Cancer Res. 2005, 11: 5481-5486.
60. Sève, P., Mackey, J., Isaac, S., Trédan, O., Souquet, P.J., Pérol, M., Lai, R., Voloch, A., Dumontet C. Class III B-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther. 2003, 4: 7001-7006.
61. Sève, P., Lai, R, Ding, K., Winton, T., Butts, C., Mackey, J., Dumontet C., Dabbagh, L., Aviel-Ronen, S., Seymour, L., Whitehead, M., Tsao, M.S., Shepherd, F.A., Reiman, T. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR0. Clin. Cancer Res. 2007, 13: 994-999.
62. Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwidek, M., Chen, T., Zhang, X.F., Seed, B., Avruch, J. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 2002, 12: 253-265.
63. Suzuki, Y., Orita, M., Shiraishi, M., Hayashi, K., Sekiya, T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990, 5: 1037-1043.
64. Ahrendt, S.A., Decker, P.A., Alawi, E.A., Zhu, Yr Y.R., Sanchez-Cespnedes, M., Yang, S.C., Haasler, G.B., Kajdacsy-Balla, A., Demeure, M.J., Sidransky, D. Cigarette smoking is strongly associated with mutantion of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001, 92: 1525-1530.
65. Rodenhuis, S., Slebos, R.J., Boot, A.J., Evers, S.G., Mooi, W.J., Wagenaar, S.S., van Bodegom, P.C., Bos, J.L. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1998, 48: 5738-5741.
66. Hynec, N.E., Lane, H.A. ERBB receptors and cancer: the complexity of targete inhibitors. Nat. Rev. Cancer 2004, 5: 341-354.
67. Salomon, D.S., Brant, R., Ciardiello, F., Normanno, N. Epidermal growth factor-related paptides and their receptors in human malignances. Crit. Rev. Oncol. Haematol. 1995, 19: 183-232.
68. Normanno, N., Bianco, C., De Luca A., Maiello, M.R., Salomon, D.S. Target-Based agent against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 2003b, 10: 1-21.
69. Pao, W., Moller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101: 13306-13311.
70. Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I.I., Fong, K.M., Lee, H., Toyooka, S., Shimizu, N., Fujisawa, T., Feng, Z., Roth, J.A., Herz, J., Minna, J.D., Gazdar, A.F. Clinical and biological features associated with epidermal growth- factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97: 339-346.
71. Han, S. W., Kim, T. Y., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D.Y., Kim, J.H., Kim, D.W., Chung, D.H., Im, S.A., Kim, Y.T. Lee, J.S., Hen, D.S., Bang, Y.J., Kim, N.K. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 2005, 23: 2493-2501.
72. Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Shibata, T., Sakiyama, T., Yoshida, T., Tamura, T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23: 6829-6837.
73. Cortes-Funes, H., Gomez, C., Rosell, R., Valero, P., Garcia-Giron, C., Velasco, A., Izquierdo, A., Diz, P., Camps, C., Castellanos, D., Alberola, V., Cardenal, F., Gonzalez-Larriba, J.L., Vieitez, J.M., Maeztu, I., Sanchez, J.J., Queralt, C., Mayo, C., Mendez, P., Moran, T., Taron, M. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small cell lung cancer patients. Ann. Oncol. 2005, 16: 1081-1086.
74. Chou, T.Y., Chiu, C.H., Li, L.H., Hsiao, C.Y., Tzen, C.Y., Chang, K.T., Chen, Y.M., Perng, R.P., Tsai, S.F., Tsai, C.M. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 2005, 11: 3750-3757.
75. Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., Yatabe, Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005, 23: 2513-2520.
76. Hirsch, F.R., Varella-Garcia, M., Bunn, P.A. Jr, Franklin, W.A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J.R., Ciuleanu, T., von Pawel, J., Watkins, C., Flannery, A., Ellison, G., Donald, E., Knight, L., Parums, D., Botwood, N., Holloway, B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 2006, 24: 5034-5042.
77. Uramoto, H., Sugio, K., Oyama, T., Ono, K., Sugaya, M., Yoshimatsu, T., Hanagiri, T., Morita, M., Yasumoto, K. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non small cell lung cancer in Japanese. Lung Cancer 2006, 51: 71-77.
78. Sone, T., Kasahara, K., Kimura, H., Nishio, K., Mizuguchi, M., Nakatsumi, Y., Shibata, K., Waseda, Y., Fujimura, M., Nakao, S. Comparative analysis of epidermal growth factor receptor mutations and gene amplifications as predictors of gefitinib efficacy in Japanese patients with non small cell lung cancer. Cancer 2007, 109: 1836-1844.
79. Bell, D.W., Lynch, T.J., Haserlat, S.M., Harris, P.L., Okimoto, R.A., Brannigan, B.W., Sgroi, D.C., Muir, B., Riemenschneider, M.J., Iacona, R.B., Krebs. A.D., Johnson, D.H., Giaccone, G., Herbst, R.S., Manegold, C., Fukuoka, M., Kris M.G., Baselga, J., Ochs, J.S., Haber, D.A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 2005, 23: 8081-8092.
80. Eberhard, D.A., Johnson, B.E., Amler, L.C., Goddard, A.D., Heldens, S.L., Herbst, R.S., Ince, W.L., Jänne, P.A., Januario, T., Johnson, D.H., Klein, P., Miller, V.A., Ostland, M.A., Ramies, D.A., Sebisanovic, D., Stinson, J,A., Zhang, Y.R., Seshagiri, S., Hillan, K.J. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 2005, 23: 5900-5909.
81. Gatzemeier, A.H., Foernzler, D., Moecks, J., Ward, C., de Rosa, F., Sauter, G., Brennscheidt, U. Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT) J. Clin. Oncol. 2005, 23: abstr 7028.
82. Riely, G.J., Pao, W., Pham, D., Li, A.R., Rizvi, N., Venkatraman E.S., Zakowski MF, Kris, M.G., Ladanyi, M., Miller, V.A. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 2006, 12: 839-844.
83. Jackman, D.M., Yeap, B.Y., Sequist, L.V., Lindeman, N., Holmes, A.J., Joshi, V.A., Bell, D.W., Huberman, M.S., Halmos, B., Rabin, M.S., Haber, D.A., Lynch, T.J., Meyerson, M., Johnson, B.E., Jänne, P.A. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 2006, 12: 3908-3914.
84. Hirsch, F.R., Franklin, W.A., McCoy, J., Cappuzzo, F., Varella-Garcia, M., Witta, S.E., Gumerlock, P., West, H., Gandara, D.R., Bunn, P.A. Jr. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. J. Clin. Oncol. 2006, 24: abstr 7072.
85. Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., Nukiwa, T. Prospective Phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 2006, 24: 3340-3346.
86. Morikawa, N., Inoue, A., Suzuki, T., Fukuhara, T., Suzuki, S., Kondo, T., Moriya, T., Saijo, Y., Nukiwa, T. Prospective analysis of the epidermal growth factor receptor gene mutations in non-small-cell lung cancer in Japan. J. Clin. Oncol. 2006, 24: Abstr 7077.
87. Sunaga, N., Yanagitani, N., Kaira, K., Tomizawa, Y., Iijima, H., Otani, Y., Tanaka, S., Suga, T., Dobashi, K., Mori, M. Phase II study of the efficacy of gefitinib in patients with non-small-cell lung cancer with the EGFR mutations. J. Clin. Oncol. 2006, 24: Abstr 7183.
88. Sutani, A., Nagai, Y., Udagawa, K, Uchida, Y., Murayama, Y., Tanaka, T., Miyazawa, H, Kanazawa, M., Hagiwara, K., Kobayashi, K. Phase II study of gefitinib, for non-small-mll lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp. J. Clin. Oncol. 2006, 24: Abstr7076.
89. Paz-Ares, L., Sanchez, J.M., García-Velasco, A., Massuti, B., López-Vivanco, G., Provencio, M., Montes, A., Isla, D., Amador, M.L., Rosell, R. Spanish Lung Cancer Group. A prospective Phase II trial of erlotinib in advanced non-small-cell lung, cancer (NSCLC) patients (p) with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. 2006, 24: Abstr 7020.
90. Douillard, J.Y., Kim, E., Hirsch, V., Mok, T., Socinski, M., Gervais, R., Wu, Y.L., Li, L., Sellers, M., Lowe, E. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). J. Thor. Oncol. 2007, 2: S305-06.
91. Crinò, L., Zatloukal, P., Reek, M., Pesek, M., Thomson, J., Ford, H., Hirsch, F., Duffield, E., Armour, A., Cullen, M. Gefifinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study: B3-04. J. Thor. Oncol. 2007, 2: S341.
92. Filipits, M. Mechanisms of cancer: multidrug resistance. Drug Discov. Today 2004, 1: 229-234.
93. Deeley, R.G., Westlake, C., Cole, S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86: 849-899.
94. Filipits, M., Haddad, V., Schmid, K., Huynh, A., Dunant, A., André, F., Brambilla, E., Stahel, R., Pignon, J.P., Soria, J.C., Popper, H.H., Le Chevalier, T., Pirker, R. Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin. Cancer Res. 2007, 13: 3992-3898.
95. Brambilla, E., Soria, J.C., Haddad, V., Lantuejoul, S., Andre, F., Filipits, M., Popper, H., Pirker, R., Le Chevalier, T., Dunant, A. Prognostic and predictive value of apoptosis related factors Fas, FasL and survivin in non small cell lung carcinoma patients enrolled in the IALT Trial. J. Thorac. Oncol. 2007, 2: 444-445.
96. Kennedy, R.D., Quinn, J.E., Johnston, P.G., Harkin, D.P. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002, 360: 1007-1014.
97. Mullan, P.B., Quinn, J.E., Gilmore, P.M., McWilliams, S., Andrews, H., Gervin, C., McCabe, N., McKenna, S., White, P., Song, Y.H. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001, 20: 6123-6131.
98. Harkin, D.P., Bean, J.M., Miklos, D., Song, Y.H., Truong, V.B., Englert, C., Christians, F.C., Ellisen, L.W., Maheswaran, S., Oliner, J.D. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999, 97: 575-586.
99. Potapova, O., Haghighi, A., Bost, F., Liu, C., Birrer, M.J., Gjerset, R., Mercola, D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 1997, 272: 14041-14044.
100. Quinn, J.E., Kennedy, R.D., Mullan, P.B., Gilmore, P.M., Carty, M., Johnston, P.G., Harkin, D.P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003, 63: 6221-6228.
101. Tassone, P., Tagliaferri, P., Perricelli, A., Blotta, S., Quaresima, B., Martelli, M.L., Goel, A., Barbieri, V., Costanzo, F., Boland, C.R., Venuta, S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast carcer cells. Br. J. Cancer 2003, 88: 1285-1291.
102. Fedier, A., Steiner, R.A., Schwarz, V.A., Lenherr, L., Haller, U., Fink, D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 2003, 22: 1169-1173.
103. Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M.S., Queralt, C., Majo, J., Sanchez, J.M., Sanchez, J.J., Maestre, J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 2004, 13(20): 2443-9.
104. Rosell, R., Skrzypski, M., Jassem, E., Taron, M., Bartolucci, R., Sanchez, J.J., Mendez, P., Chaib, I., Perez-Roca, L., Szymanowska, A., Rzyman, W., Puma, F., Kobierska-Gulida, G., Farabi, R., Jassem, J. BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer. PLoS ONE 2007, 2: e1129.
105. Sun, Z., Yang, P., Aubry, M.C., Kosari, F., Endo, C., Molina, J., Vasmatzis, G. Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung? Mol. Cancer 2004, 3: 35.
106. Wigle, D.A., Jurisica, I., Radulovich, N., Pintilie, M., Rossant, J., Liu, N., Lu, C., Woodgett, J., Seiden, I., Johnston, M., Keshavjee, S., Darling, G., Winton, T., Breitkreutz, B.J., Jorgenson, P., Tyers, M., Shepherd, F.A., Tsao, M.S. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002, 62: 3005-3008.
107. Raponi, M., Zhang, Y., Yu, J., Chen, G., Lee, G., Taylor, J.M., Macdonald, J., Thomas, D., Moskaluk, C., Wang, Y., Beer, D.G. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006, 66: 7466-7474.
108. Larsen, J.E., Pavey, S.J., Passmore, L.H., Bowman, R., Clarke, B.E., Hayward, N.K., Fong, K.M. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 2007, 28: 760-766.
109. Larsen, J.E., Pavey, S.J., Passmore, L.H., Bowman, R.V., Hayward, N.K., Fong, K.M. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin. Cancer Res. 2007, 13: 2946-2954.
110. Lu, Y., Lemon, W., Liu, P.Y., Yi, Y., Morrison, C, Yang, P., Sun, Z., Szoke, J., William, L., Gerald, W.L., Watson, M., Govindan, R., You, M. A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer. PLoS Med 2006, 3: c467.
111. Potti, A., Mukherjee, S., Petersen, R., Dressman, H.K., Bild, A., Koontz, J., Kratzke, R., Watson, M.A., Kelley, M., Ginsburg, G.S., West, M., Harpole, D.H. Jr, Nevins, J.R. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 2006, 355: 570-580.